BRPI0822580A2 - Composto, recipiente, processo para produzir uma composição, uso de uma composição, e, método para controle ou prevenção de doenças infecciosas. - Google Patents

Composto, recipiente, processo para produzir uma composição, uso de uma composição, e, método para controle ou prevenção de doenças infecciosas.

Info

Publication number: BRPI0822580A2
Authority: BR; Brazil
Prior art keywords: composition; container; compound; producing; controlling
Prior art date: 2008-04-08

Application number

BRPI0822580-0A

Other languages

English (en)

Inventor

Dieter Gillessen

Jürgen Jäger

Original Assignee

Acino Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-08

Filing date

2008-04-08

Publication date

2015-06-23

2008-04-08 Application filed by Acino Pharma Ag filed Critical Acino Pharma Ag

2015-06-23 Publication of BRPI0822580A2 publication Critical patent/BRPI0822580A2/pt

Links

208000035473 Communicable disease Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
HWJPWWYTGBZDEG-UHFFFAOYSA-N 5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine Chemical compound C=12C=CC(C3CC3)OC2=C(OC)C(OC)=CC=1CC1=CN=C(N)N=C1N HWJPWWYTGBZDEG-UHFFFAOYSA-N 0.000 abstract 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
238000001914 filtration Methods 0.000 abstract 1
238000001802 infusion Methods 0.000 abstract 1
238000002347 injection Methods 0.000 abstract 1
239000007924 injection Substances 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
229940069328 povidone Drugs 0.000 abstract 1
239000011780 sodium chloride Substances 0.000 abstract 1
239000000243 solution Substances 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Dermatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BRPI0822580-0A 2008-04-08 2008-04-08 Composto, recipiente, processo para produzir uma composição, uso de uma composição, e, método para controle ou prevenção de doenças infecciosas. BRPI0822580A2 (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/EP2008/054232 WO2009124586A1 (en)	2008-04-08	2008-04-08	Aqueous pharmaceutical formulation

Publications (1)

Publication Number	Publication Date
BRPI0822580A2 true BRPI0822580A2 (pt)	2015-06-23

Family

ID=40239668

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0822580-0A BRPI0822580A2 (pt)	2008-04-08	2008-04-08	Composto, recipiente, processo para produzir uma composição, uso de uma composição, e, método para controle ou prevenção de doenças infecciosas.

Country Status (12)

Country	Link
EP (1)	EP2280688B1 (pt)
JP (1)	JP2011516509A (pt)
KR (1)	KR20110008055A (pt)
CN (1)	CN102112108A (pt)
AT (1)	ATE542522T1 (pt)
AU (1)	AU2008354622A1 (pt)
BR (1)	BRPI0822580A2 (pt)
CA (1)	CA2721014A1 (pt)
MX (1)	MX2010011117A (pt)
TW (1)	TW200942240A (pt)
WO (1)	WO2009124586A1 (pt)
ZA (1)	ZA201007185B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX388963B (es)	2011-03-04	2025-03-20	Gruenenthal Gmbh	Formulacion farmaceutica acuosa de tapentadol para administracion oral
GB201212010D0 (en) *	2012-07-05	2012-08-22	Sigmoid Pharma Ltd	Formulations
PE20171651A1 (es)	2015-03-27	2017-11-13	Gruenenthal Chemie	Formulacion estable para administracion parenteral de tapentadol
EP3120837A1 (de)	2015-07-22	2017-01-25	Stada Arzneimittel Ag	Verfahren zur herstellung einer bortezomibester-lösung
US10076522B2 (en) *	2016-05-04	2018-09-18	Motif BioSciences Inc.	Systems and methods for treating bacterial infection
EP3515412B1 (en)	2016-09-23	2025-04-23	Grünenthal GmbH	Stable formulation for parenteral administration of tapentadol
CN110818693B (zh) *	2018-08-07	2023-06-02	上海度德医药科技有限公司	一种艾拉普林甲磺酸盐晶型b及其制备方法
WO2020161284A1 (en)	2019-02-07	2020-08-13	Sandoz Ag	Crystalline form of iclaprim mesylate
CN110642792B (zh) *	2019-11-18	2023-04-21	上海医药工业研究院有限公司	艾拉普林中间体的制备方法
CN110790753B (zh) *	2019-11-18	2023-04-07	上海医药工业研究院	艾拉普林对甲苯磺酸盐、其制备方法和应用
CN110713483B (zh) *	2019-11-18	2023-04-07	上海医药工业研究院	艾拉普林中间体及艾拉普林的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0866791T3 (da) *	1995-12-04	2002-04-22	Arpida Ag	Diaminopyrimidiner, farmaceutiske præparater indeholdende disse og deres anvendelse som antibakterielle midler
WO2005014586A1 (en) *	2003-08-08	2005-02-17	Arpida Ag	Novel process for the preparation of 2h-chromenes
KR20070106636A (ko) *	2005-02-18	2007-11-02	아르피다 아게	벤조퓨란의 제조를 위한 신규한 방법들

2008
- 2008-04-08 EP EP08735958A patent/EP2280688B1/en not_active Not-in-force
- 2008-04-08 CA CA2721014A patent/CA2721014A1/en not_active Abandoned
- 2008-04-08 MX MX2010011117A patent/MX2010011117A/es unknown
- 2008-04-08 TW TW097112657A patent/TW200942240A/zh unknown
- 2008-04-08 JP JP2011503341A patent/JP2011516509A/ja active Pending
- 2008-04-08 WO PCT/EP2008/054232 patent/WO2009124586A1/en not_active Ceased
- 2008-04-08 CN CN2008801294274A patent/CN102112108A/zh active Pending
- 2008-04-08 AT AT08735958T patent/ATE542522T1/de active
- 2008-04-08 AU AU2008354622A patent/AU2008354622A1/en not_active Abandoned
- 2008-04-08 BR BRPI0822580-0A patent/BRPI0822580A2/pt not_active IP Right Cessation
- 2008-04-08 KR KR1020107023886A patent/KR20110008055A/ko not_active Withdrawn
2010
- 2010-10-07 ZA ZA2010/07185A patent/ZA201007185B/en unknown

Also Published As

Publication number	Publication date
EP2280688B1 (en)	2012-01-25
JP2011516509A (ja)	2011-05-26
WO2009124586A1 (en)	2009-10-15
CA2721014A1 (en)	2009-10-15
EP2280688A1 (en)	2011-02-09
ZA201007185B (en)	2013-03-27
ATE542522T1 (de)	2012-02-15
KR20110008055A (ko)	2011-01-25
TW200942240A (en)	2009-10-16
MX2010011117A (es)	2011-02-24
AU2008354622A1 (en)	2009-10-15
CN102112108A (zh)	2011-06-29

Similar Documents

Publication	Publication Date	Title
BRPI0822580A2 (pt)	2015-06-23	Composto, recipiente, processo para produzir uma composição, uso de uma composição, e, método para controle ou prevenção de doenças infecciosas.
RU2013123457A (ru)	2014-12-27	Непрерывное введение l-допа, ингибиторов допа-декарбоксилазы, ингибиторов катехол-о-метилтрансферазы и предназначенные для этого композиции
PE20110419A1 (es)	2011-07-13	Compuestos de pirrolo-pirimidina como inhibidores de cdk
RU2011153403A (ru)	2013-07-20	Стабилизированная композиция, содержащая по меньшей мере одно адренергическое соединение
EA200900896A1 (ru)	2010-04-30	Соединения-агонисты гетероциклических рецепторов (варианты), фармацевтическая композиция на их основе, способ лечения диабета и метаболических расстройств, способ стимулирования выработки инсулина (варианты) и способы снижения уровня глюкозы и триглицеридов в крови посредством указанных соединений
EA201200952A1 (ru)	2013-02-28	Производные пиразина и их применение для лечения неврологических нарушений
MX336757B (es)	2016-01-29	Metodo para la produccion de la composicion de acido hipocloroso y aplicaciones.
PE20141038A1 (es)	2014-09-05	Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida
NZ702093A (en)	2017-08-25	Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
AR070487A1 (es)	2010-04-07	Derivados de 3- metil- imidazo -( 1,2-b)- piridazina
NZ598085A (en)	2014-02-28	Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
EA201490175A1 (ru)	2014-06-30	Составы дезоксихолевой кислоты и ее солей
PH12012501402A1 (en)	2016-07-27	Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
NO20076425L (no)	2008-01-30	Fremgangsmater for behandling av drug-resistent cancer
FI2034956T4 (fi)	2023-08-31	Matalan viskositeetin omaavia glykosaminoglykaaneja käsittäviä koostumuksia ja mainitun koostumuksen käyttö kroonisen kystiitin terapiassa
UA117480C2 (uk)	2018-08-10	Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
MX2012001529A (es)	2012-02-29	Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-piridazin-6-ilo como moduladores de cinasa de tirosina c-met.
EA200901141A1 (ru)	2010-04-30	Соли присоединения с кислотами, гидраты и полиморфные формы этидамида 5-(2,4-дигидрокси-5-изопропилфенил)-4-(4-морфолин-4-илметилфенил)изоксазол-3-карбоновой кислоты и препараты, содержащие эти формы
RU2015112121A (ru)	2016-10-27	Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
NO20061460L (no)	2006-07-03	Legemiddel inneholdende (2R)-2-propyloktansyre som den aktive bestanddel
WO2009051217A1 (ja)	2009-04-23	フェンタニル含有経皮吸収製剤
SE0301577D0 (sv)	2003-05-28	Low sodium solution
CN103637980B (zh)	2016-01-13	一种盐酸异丙嗪注射液的制备方法
SE0600091L (sv)	2007-04-17	Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin
CO6270205A2 (es)	2011-04-20	Formulacion que contiene un compuesto inhibidor de quinasa dependiente de ciclina y metodo para tratar tumores utilizando el mismo

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 3A, 6A E 7A ANUIDADES.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.